93 results
Page 3 of 5
8-K
EX-5.1
ph5ec5e 8tpuq
19 Jul 22
Entry into a Material Definitive Agreement
9:34pm
8-K
EX-1.1
ntmmcknnw98muo04vzoq
19 Jul 22
Entry into a Material Definitive Agreement
9:34pm
POS AM
0f3xzu 97
22 Jun 22
Prospectus update (post-effective amendment)
5:19pm
8-K12B
EX-10.1
4d3ydb
16 Jun 22
Notification of registration of securities
8:15am
POS AM
eiyz 4eqvf3muk593
28 Mar 22
Prospectus update (post-effective amendment)
8:46am
DEFA14A
EX-2.1
fwvduo0pqyqb
22 Feb 22
Additional proxy soliciting materials
8:04am
8-K
EX-2.1
z1hkr4371os
22 Feb 22
Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end
8:03am
8-K
EX-5.1
yxzilc2bsu0b
2 Jul 21
Panbela Therapeutics Announces $5.0 Million Bought Deal Offering of Common Stock
4:06pm
8-K
EX-1.1
qwyrpi3imdn
2 Jul 21
Panbela Therapeutics Announces $5.0 Million Bought Deal Offering of Common Stock
4:06pm
S-8
EX-99.1
owjn2 x16wvdc3nkq
20 Apr 21
Registration of securities for employees
4:53pm
POS AM
w0b9vx
26 Mar 21
Prospectus update (post-effective amendment)
12:00am
8-K
EX-4.1
azmle kyha
1 Sep 20
Sun BioPharma, Inc. Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:12pm
8-K
EX-1.1
4nwqd
1 Sep 20
Sun BioPharma, Inc. Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:12pm